Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of disease free stage III or stage IV melanoma (with or without metastases) or stable disease (if with metastases) and receiving no other treatment~* willing to use effective contraception for the duration of the study~* able to comply with the requirement to complete a diary card~Exclusion Criteria:~* Pregnant or lactating females~* Major surgery within the 14 days preceding the screening visit~* Suspicion of a previous infection with mycobacteria including previous tuberculosis (TB) prophylaxis~* Treatment with another investigational medicinal product within the last 30 days prior to the screening visit~* Previous treatment with M. vaccae~* Exposure to Bacille Calmette Guérin vaccine (BCG) within the last 12 months~* Concurrent uses of drugs likely to reduce inflammation at the local injection site or dampen/modulate the immune system~* Depot injection of corticosteroids within 6 weeks of the screening visit or chronic systemic corticosteroids in the 2 weeks prior to the screening visit~* Ongoing treatment with radiotherapy, cytotoxic chemotherapy or chemotherapy in the last 30 days prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMM-101 (Type: EXPERIMENTAL): Patients received an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28. Doses used were:~'Heat killed whole cell M. obuense (IMM-101) 0.1 mg', 'Heat killed whole cell M. obuense (IMM-101) 0.5 mg', or 'Heat killed whole cell M. obuense (IMM-101) 1.0 mg'

Based on this trial design, predict the completion outcome and termination type (if applicable).